In this new episode of the pharmaphorum podcast, host Nicole Raleigh speaks with James Burt, CEO of Pharmanovia, about the value-added medicines space.
The detrimental issues within health systems in developing countries have become intrinsic to their model, with lack of funding and resources, as well as systemic issues, causing inequality
Astellas has added another gene therapy to its pipeline, taking an option on a clinical-stage candidate for a rare genetic form of dementia from UK biotech AviadoBio for around $50 million.
